liraglutide: Head-to-head study reveals a diabetes risk difference GLP-1 weight-loss drugs may also reduce binge eating The 5:2 intermittent fasting diet involves two nonconsecutive fasting days (one-fourth of the energy intake of a habitual diet) and five days of habitual intake per week
Dr Del Genios research aims to design innovative biomaterials with potential applications in drug delivery and anticancer strategies
The over-arching ideas and conclusions from both studies as to how certain protein interactions influence ageing appear to back each other up
Having new oral agents that lower glucose but also meaningfully lower weight well beyond levels seen with most existing diabetes therapies is critical to future type 2 diabetes care, echoed Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, in a statement
The goal is to find the minimum effective dose that provides the desired results with minimal side effects
These findings position GLP-1RAs as a potential fourth pillar of kidney-protective therapy in diabetes, alongside renin-angiotensin system inhibitors (RASi), SGLT2i, and finerenone, and suggest a shift toward rapid initiation of combination therapies for maximum kidney protection
